Pancreatic neoplasia is the fifth most common cancer in the United States. Its etiology is largely unknown and no curative treatment is presently available. Over-expression of epidermal growth factor receptor (EGFR) occurs in approximately 90% of human pancreatic cancer. EGFR over-expression or activation leads to the activation of Akt and NF-kappaB signaling pathways, suggesting that these pathways are important therapeutic targets for pancreas cancer. Activation of Akt/NF-kappaB in pancreatic cancer induces downstream target genes, such as uPA, VEGF, IL-8 and Bcl-xl that may mediate its cardinal clinical features of locally aggressive growth, metastasis, and chemotherapy resistance. We have recently observed that genistein is a potent inhibitor of Akt/NF-kappaB pathway and inducer of apoptotic cell death. Our microarray data from cells treated with genistein showed inactivation of NF-kappaB downstream genes that are important in angiogenesis, invasion and metastasis (Cancer Letters 186:157, 2002). In addition, we have recently discovered a new cDNA that codes for ERRP. ERRP is believed to attenuate the EGFR function by sequestration of EGFR ligands, and that the ERRP could be upregulated by genistein treatment of pancreatic cancer cells. Our results also suggest that treatment of pancreatic cancer cells with either genistein or ERRP or their combinations may induce apoptotic cell death, and may also sensitize pancreatic cancer cells to commonly used chemotherapeutic agents, such as cisplatin and gemcitabine. Collectively, these findings strongly suggest that the inactivation of the EGFR/Akt/NF-kappaB pathways should be very important for devising therapeutic strategies for pancreatic cancer, which could be accomplished by our novel approach (genistein and ERRP treatment). Based on our preliminary data, we hypothesize that ERRP is a negative regulator of EGFR that inhibits proliferation and stimulates apoptosis by attenuating EGFR signaling. We further hypothesize that inactivation of Akt/NF-kappaB signaling, which is a downstream signaling pathway of EGFR, by genistein may potentiate the activity of ERRP treatment in pancreatic cancer cells, and may also sensitize these cells to cisplatin and/or gemcitabine. To test our hypothesis, we will determine how ERRP inactivates EGFR signaling, and also determine the effects of ERRP and genistein on cell growth inhibition and induction of apoptosis, and correlate these results with inactivation of Akt and NF-kappaB. Moreover, we will determine the cause and effect relationships between cell growth inhibition and apoptosis inducing activity of genistein and ERRP with Akt/NF-kappaB signaling, by gene transfection experiments. We will also test whether the inactivation of Akt/NF-kappaB by genistein and/or ERRP could sensitize pancreatic cancer cells to cisplatin and gemcitabine-induced apoptosis. Finally, we will test whether the treatment effects of these agents alone or in combinations with or without cisplatin and gemcitabine will inhibit tumor growth in SCID xenografts. These results will provide mechanistic as well as pre-clinical data in support of our hypotheses and may open new and novel avenues for the treatment of human pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA101870-04
Application #
7109330
Study Section
Special Emphasis Panel (ZRG1-GMA-3 (01))
Program Officer
Arya, Suresh
Project Start
2003-08-01
Project End
2008-05-31
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
4
Fiscal Year
2006
Total Cost
$328,079
Indirect Cost
Name
Wayne State University
Department
Pathology
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Bao, Bin; Ahmad, Aamir; Azmi, Asfar S et al. (2013) Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol Chapter 14:Unit 14.25
Shamim, Uzma; Hanif, Sarmad; Albanyan, Abdulmajeed et al. (2012) Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. J Cell Physiol 227:1493-500
Bao, Bin; Ali, Shadan; Banerjee, Sanjeev et al. (2012) Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72:335-45
Azmi, Asfar S; Beck, Frances W J; Bao, Bin et al. (2011) Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Epigenomics 3:747-59
Azmi, A S; Philip, P A; Beck, F W J et al. (2011) MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene 30:117-26
Banerjee, Sanjeev; Kong, Dejuan; Wang, Zhiwei et al. (2011) Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic. Mutat Res 728:47-66
Wang, Zhiwei; Li, Yiwei; Ahmad, Aamir et al. (2011) Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem 112:78-88
Azmi, Asfar S; Banerjee, Sanjeev; Ali, Shadan et al. (2011) Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget 2:378-92
Wang, Zhiwei; Ahmad, Aamir; Li, Yiwei et al. (2011) Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res 31:1105-13
Kong, Dejuan; Li, Yiwei; Wang, Zhiwei et al. (2011) Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) 3:716-29

Showing the most recent 10 out of 68 publications